Sumitomo Pharma Co., Ltd. 的 Form 4 申報
Myovant Sciences Ltd.（MYOV），2021/8/24 申報
- 申報編號
- 0000899243-21-034046
- 申報時間
- 2021/8/24 17:00 ET
- 交易日
- 2021/8/20-8/23
- 申報延遲
- 4 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 3 筆非衍生性交易。公開市場買進合計 $220.6 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Sumitomo Pharma Co., Ltd.CIK 0001446601 | 持股 10% 以上大股東 |
| Sumitovant Biopharma Ltd.CIK 0001798244 | 持股 10% 以上大股東 |
| Sumitomo Chemical Co., Ltd.CIK 0001798550 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The transaction was executed in multiple trades ranging from $20.32 to $21.27 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The transaction was executed in multiple trades ranging from $21.36 to $22.35 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。
- F7
The transaction was executed in multiple trades ranging from $22.36 to $22.66 per share. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected.
表 I 有 1 筆交易的價格引用這則附註。